Life Sciences Partners leads €31.7m series-A for Immunic

Life science investors Omega and Fund+ joined the round last and contributed €10m. LSP led the round, which initially closed on €17.5m in September 2016.

Also taking part in the round are financial investors Bayern Kapital, High-Tech Gründerfonds and IBG Risikokapitalfonds II.

The fresh capital will be used to further the clinical development of two drugs designed for chronic inflammatory and autoimmune diseases, IMU-838 and IMU-366.

The company claims it is one of Europe's largest series-A financing rounds in the biotechnology industry. According to unquote" data, it is the 15th largest series-A funding round for a biotechnology company in the DACH region.

Company
Founded in 2016 and based in Planegg-Martinsried, Immunic develops medicine for the treatment of immune and autoimmune diseases, such as inflammatory bowel disease or psoriasis.

People
Life Sciences Partners – Jörg Neermann (partner).
High-Tech Gründerfonds – Lena Krzyzak (investment manager).
Immunic – Manfred Gröppel (co-founder).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• Germany
• Life Science Partners
• High-Tech Gründerfonds
• Venture